Galera Therapeutics Inc. (GRTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 45 LIBERTY BLVD.
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,257,00031,597,00071,217,00072,776,000112,290,000
Cash and cash equivalents18,257,0004,266,00019,859,00015,872,00018,356,000
Short-term investments  27,331,00051,358,00056,904,00093,934,000
Restricted cash and investments  50,000   
Prepaid expense1,450,000    
Other undisclosed current assets 1,922,0006,888,0006,175,0005,153,0005,280,000
Total current assets:21,629,00038,535,00077,392,00077,929,000117,570,000
Noncurrent Assets
Operating lease, right-of-use asset 1,212,00043,000296,000530,000815,000
Property, plant and equipment 71,000438,000527,0001,023,000934,000
Intangible assets, net (including goodwill) 3,139,0003,139,0003,139,0003,139,0003,139,000
Goodwill 881,000881,000881,000881,000881,000
Intangible assets, net (excluding goodwill) 2,258,0002,258,0002,258,0002,258,0002,258,000
Other noncurrent assets90,0001,881,0001,957,0001,477,000918,000
Total noncurrent assets:4,512,0005,501,0005,919,0006,169,0005,806,000
TOTAL ASSETS:26,141,00044,036,00083,311,00084,098,000123,376,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,824,00013,335,00012,677,00013,730,0009,397,000
Accounts payable1,375,0003,581,0005,044,0005,146,0003,945,000
Accrued liabilities3,449,0009,754,0007,633,0008,584,0005,452,000
Debt 133,00044,000258,000238,000297,000
Total current liabilities:4,957,00013,379,00012,935,00013,968,0009,694,000
Noncurrent Liabilities
Long-term debt and lease obligation:   44,000296,000534,000
Liabilities, other than long-term debt 1,117,000    
Operating lease, liability 1,117,000 44,000296,000534,000
Other undisclosed noncurrent liabilities151,252,000139,838,000128,292,00063,420,00043,540,000
Total noncurrent liabilities:152,369,000139,838,000128,380,00064,012,00044,074,000
Total liabilities:157,326,000153,217,000141,315,00077,980,00053,768,000
Equity
Equity, attributable to parent(131,185,000)(109,181,000)(58,004,000)6,118,00069,608,000
Common stock54,00028,00026,00025,00025,000
Additional paid in capital306,167,000269,137,000258,086,000241,649,000230,895,000
Accumulated other comprehensive income (loss)  (22,000)(14,000)12,00038,000
Accumulated deficit(437,406,000)(378,324,000)(316,102,000)(235,568,000)(161,350,000)
Total equity:(131,185,000)(109,181,000)(58,004,000)6,118,00069,608,000
TOTAL LIABILITIES AND EQUITY:26,141,00044,036,00083,311,00084,098,000123,376,000

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(46,951,000)(51,226,000)(73,368,000)(70,553,000)(50,691,000)
Other undisclosed operating loss (2,309,000)    
Operating loss:(49,260,000)(51,226,000)(73,368,000)(70,553,000)(50,691,000)
Nonoperating income1,592,000505,00028,0001,199,0001,783,000
Investment income, nonoperating1,595,000506,00032,0001,174,0001,823,000
Interest and debt expense(11,414,000)(11,571,000)(7,194,000)(4,880,000)(3,031,000)
Loss from continuing operations before income taxes:(59,082,000)(62,292,000)(80,534,000)(74,234,000)(51,939,000)
Income tax expense (benefit) (70,000) 16,0009,000
Loss from continuing operations:(59,082,000)(62,362,000)(80,534,000)(74,218,000)(51,930,000)
Loss before gain (loss) on sale of properties:(80,534,000)(74,218,000)(51,930,000)
Other undisclosed net income  140,000   
Net loss attributable to parent:(59,082,000)(62,222,000)(80,534,000)(74,218,000)(51,930,000)
Preferred stock dividends and other adjustments     (7,176,000)
Net loss available to common stockholders, diluted:(59,082,000)(62,222,000)(80,534,000)(74,218,000)(59,106,000)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(59,082,000)(62,222,000)(80,534,000)(74,218,000)(51,930,000)
Comprehensive loss:(59,082,000)(62,222,000)(80,534,000)(74,218,000)(51,930,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 22,000(8,000)(26,000)(26,000)35,000
Comprehensive loss, net of tax, attributable to parent:(59,060,000)(62,230,000)(80,560,000)(74,244,000)(51,895,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: